Objectives The aim of this study was to estimate the comparative safety of initiating commonly used opioids among older, long-stay United States nursing home residents with fracture hospitalizations. Methods We conducted a new-user retrospective cohort study of nursing home residents initiating short-acting oxycodone, hydrocodone, or tramadol by merging the 2011-2013 Minimum Data Set 3.0 to Medicare hospitalization and pharmacy claims. Residents (≥ 65 years, no cancer or hospice use) contributed treatment episodes (> 120 days with no prior opioid claims) and were followed for 180 days until incident fracture hospitalization (hip, femur, humerus, pelvis, radius/ulna), death (competing risk), treatment changes (e.g., discontinuation), or administrative censoring. Competing risks models with inverse probability of treatment weighting were used to estimate subdistribution hazard ratios (HR SD ) and 95% confidence intervals (CI). Results Overall, 110,862 residents contributed 134,432 treatment episodes: 14,373 oxycodone; 69,182 hydrocodone; and 50,877 tramadol initiators. The incidences of fracture hospitalizations per 100 person-years were 9.4 (95% CI 7.5-11.7) for oxycodone, 7.9 (95% CI 7.1-8.8) for hydrocodone, and 5.0 (95% CI 4.3-5.7) for tramadol initiators. In weighted models, oxycodone initiators had a similar rate of fractures to hydrocodone initiators (HR SD 1.08, 95% CI 0.79-1.48). Tramadol initiators had lower fracture rates than hydrocodone initiators (HR SD 0.67, 95% CI 0.56-0.80). Conclusions The lower rate of fractures that we documented among tramadol initiators compared with hydrocodone initiators is consistent, albeit attenuated compared with prior studies among community-dwelling older adults. However, overall fracture rates were lower than in community settings, potentially due to the limited risk of falling in this population with limited mobility.
Introduction
Globally, prescription opioid use in long-term care facilities has increased over time [1] , with one-third of older United States (US) nursing home residents prescribed an opioid during 2011-2012 to manage their non-malignant pain [2, 3] . Fifteen percent of US nursing home residents were prescribed opioids long-term [2] , more than two-fold the prevalence documented in community settings [4, 5] . Acute and long-term opioid use may be necessary in this vulnerable population given the high burden of painful comorbidities and concerns of the consequences of undertreating pain [6] [7] [8] . Further, these practices are consistent with 2009 American Geriatrics Society guidelines recommending that "all patients with moderate to severe pain, pain-related functional impairment, or diminished quality of life due to pain should be considered for opioid therapy". However, these strong recommendations are supported by limited evidence to guide clinical decision-making on which opioids to initiate, particularly among older, medically complex nursing home residents.
Short-acting formulations of oxycodone, hydrocodone, and tramadol are prescribed to > 80% of residents initiating opioids in US nursing homes [3] . These medications have varying pharmacokinetic and pharmacodynamic profiles including affinity for μ-opioid receptors, metabolic pathways, bio-availability, and elimination half-lives [9] [10] [11] . Such differences may affect time to onset of effect, potency, duration of analgesia, and ultimately the risk of safety events such as fractures (e.g., by impairing cognition, coordination, and balance leading to falls). In community-dwelling older adults, persons initiating tramadol had lower fracture risk compared with hydrocodone initiators, especially in the first 30 days [12] . Oxycodone initiators had similar fracture risk to hydrocodone initiators [12] . It is unclear if such findings extend to older nursing home residents due to differences in age, disease burden, complex drug regimens, and overall frailty in comparison with community-dwelling adults [13] [14] [15] [16] . Yet, fractures are common and have devastating consequences in nursing homes. Three percent of long-stay residents will experience a hip fracture within 2 years [17] , with survivors suffering from pressure ulcers and infections, functional decline, and mortality [18] [19] [20] [21] . Other fracture hospitalizations may also be devastating but have been understudied in this care setting.
Given the wide use of opioids in nursing homes and residents' increased risk of adverse drug events including fractures, understanding the comparative safety of commonly used opioids in nursing homes is critical. Therefore, we conducted this study to evaluate the risk of major fracture hospitalizations following the initiation of short-acting oxycodone, hydrocodone, or tramadol.
Methods
The University of Massachusetts Medical School Institutional Review Board approved this study.
Data Sources
We conducted a retrospective cohort study using 2011-2013 Minimum Data Set (MDS) 3.0 merged to the Master Beneficiary Summary File (MBSF; contains Medicare enrollment and death information), Medicare Part A hospitalization claims, and Part D pharmacy claims (including generic drug names, fill date, days' supply, and dosage strength). The MDS 3.0 is a federally required assessment of all US nursing residents living in US Medicare-and/or Medicaid-certified nursing homes (~ 96% of all homes). Registered nurses conduct comprehensive assessments at admission, annually, and whenever there is a change in clinical status, and condensed quarterly assessments (with a subset of items) at 90-day intervals. Nurses collect information by reviewing residents' medical record and interviewing residents with validated instruments to collect information on comorbidities, cognitive and physical functioning, pain, mood, and other measures [22] [23] [24] . MDS 3.0 measures have demonstrated validity and reliability [22] .
Treatment Groups and Study Population
Our study cohort included Medicare beneficiaries who were long-stay nursing home residents (≥ 120 consecutive days in facility) and who initiated short-acting oral formulations of hydrocodone, oxycodone, or tramadol between March 31, 2011 and December 31, 2013. Initiation was defined as being prescribed a study drug with no prior prescriptions of any opioid in the 120 days before the initiating fill date (index date; see Supplementary Tables 1, 2 in the electronic  supplementary material [ESM] for further information on study and non-study opioids). We focused on these medications because they were the three most commonly used short-acting opioids in US nursing homes during the study period [2] , though they differed in drug scheduling (oxycodone: schedule II, hydrocodone: schedule III, tramadol: unscheduled). Eligible residents had Medicare Part A, B, and D coverage and no Medicare Advantage plan in the 4 months before initiating the aforementioned drugs; these criteria were implemented to reduce concerns of incomplete (i.e., missing) hospitalization claims [25] .
The unit of analysis was a treatment episode. As such, residents could contribute multiple treatment episodes if they met our inclusion/exclusion criteria. We excluded treatment episodes with no MDS assessment (quarterly or comprehensive) in the 120 days preceding opioid initiation or no comprehensive assessment in the prior year; those who were recently hospitalized and/or received skilled nursing facility care within 120 days preceding opioid initiation; those living in provider-based facilities and free-standing skilled nursing facilities; treatment episodes where the resident was < 65 years old at initiation or were comatose, had cancer, received hospice care, or had missing data on potential confounders; and those initiating unusually high opioid doses > 180 mg of oral morphine equivalents (OME) [26, 27] . In addition, states/districts contributing < 100 treatment episodes to the analysis (Alaska, Washington DC) and states where < 2% of treatment episodes were oxycodone (Illinois, Michigan, Texas) were also excluded. Further details on inclusion/exclusion criteria and study design overview are displayed in Supplementary Appendix 1 and Supplementary  Fig. 1 in the ESM, respectively.
Opioid Use: Initiating Dose and Follow-up

Initiating Dose
Average daily dose of the oxycodone, hydrocodone, or tramadol prescriptions initiated on the index date was calculated by multiplying dosage strength in OME and quantity dispensed and then dividing by days' supply. Oral morphine conversion factors used for oxycodone, hydrocodone, and tramadol were 1.0, 1.5, and 0.1, respectively [28] . Doses were categorized as < 25 mg, 25-49 mg, and ≥ 50 mg OME/ day. Although unconventional, these categorizations were chosen because most residents initiate lower doses than community-dwelling adults [3, 29, 30] . Doses ≥ 50 mg OME/day are considered potentially inappropriate in persons initiating opioids for chronic non-cancer pain outside of the context of palliative or end-of-life care [31] .
Follow-up
We were interested in estimating the as-treated effect of commonly initiated opioids on fracture hospitalizations within 180 days of opioid initiation. Residents contributed follow-up time to analyses based on the number of days from the prescription fill date and the earliest of the following: experiencing the study outcome of interest (incident fracture hospitalizations); death (a competing event, described below); changes in opioid treatment including discontinuation, switching treatment groups, or initiating a non-study opioid; enrolling in Medicare Advantage; reaching end of follow-up (December 31, 2013); or 180 days of treatment. Residents were assumed to take opioids as prescribed from the fill date through to the end of the prescription days' supply. We allotted a 7-day grace period between prescription fills (in which a resident was still at risk for the outcome). If a resident filled a subsequent prescription before the calculated end date of the previous prescription, we assumed the new prescription began after the calculated end date of the old prescription. Residents who discontinued initial treatment could re-enter (and change treatment groups) if a later treatment episode met eligibility criteria.
Fracture Hospitalizations
The outcome of interest was fracture hospitalizations within 180 days of treatment initiation. We used Part A hospitalization claims diagnosis codes to create a composite outcome for major fracture hospitalizations, including femur, hip, humerus, pelvis, or radius/ulna fractures. Although certain fractures (e.g., radius/ulna) may be less likely to result in hospitalization than others (e.g., hip), they are all clinically significant and are among the most common injuries leading to hospitalizations in older adults [32] . External validation studies were used to define fractures using International Classification of Diseases, 9th edition codes (positive predictive value for hip fractures ≥ 87%; see Supplementary Table 3 [see ESM] for specific definitions used for each fracture type) [33, 34] . Except for hip fractures, we did not use procedure codes to identify the study outcome because we did not have outpatient claims available. If during a treatment episode a resident had multiple fracture hospitalizations, only the first hospitalization was included in the analysis.
Competing Risks
Traditional survival analysis techniques such as Kaplan-Meier curves and Cox proportional hazards models assume that censored study participants have the same survival experience as those remaining in the study [35] . Competing risks violate this assumption because they are events that preclude the study outcome [36] , and analyses that ignore competing risks will overestimate cumulative incidence (the complement of the survival curve). Because residents who die cannot be hospitalized for fractures, we treated death as a competing event, measured using the date of death in the MBSF.
Potential Confounders
We adjusted for variables that we thought might be confounders based on clinical expertise (JT, ALH) and prior literature identifying risk factors for fractures in US nursing homes [37] . Potential confounders were ascertained from Part D claims and the most recent MDS assessment in the 120 days preceding opioid initiation [37] . Because certain chronic comorbidities (e.g., arthritis, osteoporosis) were not included on quarterly assessments, the most recent comprehensive assessment within 365 days preceding opioid initiation was used for these conditions.
Prior MDS assessments provided information about state of residence [38] ; resident demographics (age [included as a continuous variable and quadratic term], gender, race/ethnicity); cognitive impairment [39] and other measures of cognitive functioning (attention, disorganized thinking); physical functioning [40] including the MDS Activities of Daily Living Self-performance hierarchy and specific measures of physical functioning for transferring between surfaces, locomotion on unit, and locomotion off unit; self-or staffassessed pain; behaviors (rejecting care, wandering); urinary and bowel incontinence; mobility device use (wheelchairs, cane/walker); oxygen use; unplanned weight loss; comorbidities associated with falls or fractures (e.g., dementia; history of falls); and anxiolytic and hypnotic use (because benzodiazepines were not covered by Medicare during 2011-2012).
Part D data was used to identify overall medications prescribed in the 120 days before opioid initiation and other medications that may be associated with fractures either directly or as proxies for medical conditions associated with fractures. This includes psychotropic medications (e.g., antipsychotics), pain adjuvants (e.g., skeletal muscle relaxants), cardiovascular medications (e.g., beta blockers), diabetic medications (e.g., sulfonylureas), gastric medications (e.g., proton pump inhibitors), dementia medications (e.g., cholinesterase inhibitors), osteoporosis medications, and Parkinson's medications. See Supplementary Table 4 in the ESM for further detail on specific resident characteristics included as potential confounders.
Statistical Analysis
We examined the distribution of potential confounders across the three treatment groups and calculated standardized mean differences (SMDs), first by calculating each pairwise treatment contrast and then averaging all three treatment contrasts. SMDs measure the differences in means/ proportions between treatment groups in units of pooled standard deviation and are uninfluenced by sample size; covariates with SMDs > 0.1 are generally considered meaningfully imbalanced [41] .
To adjust for potential confounders, we estimated propensity scores generalized to multiple treatment groups and implemented with inverse probability of treatment (IPT) weighting [42, 43] . A propensity score is the probability of treatment given measured covariates and was estimated using a multinomial model that included main terms for state of residence and potential resident confounders. We estimated stabilized IPT weights for each treatment episode by dividing the overall probability of treatment by the resident's propensity score of being prescribed the treatment they received [44] . Our IPT-weighting standardized the distribution of measured confounders within each treatment group to that of the entire study population [45] . We evaluated our IPT weights by comparing the propensity score distributions of initiating each study drug before and after weighting and comparing the SMDs of the potential baseline confounder in the crude and weighted sample [41] .
We fit Poisson models to estimate crude and weighted incidence rates of fracture hospitalizations per 100-person years by treatment group. We then fit Fine and Gray competing risks models to estimate crude and weighted cumulative risks and subdistribution hazards ratios (HR SD ) for initiating commonly used opioids on fracture hospitalization risk within 180 days of treatment initiation [46] . For HR SD , robust 95% confidence intervals (CIs) were used to account for weighting and clustering of multiple treatment episodes within residents. We determined that the proportional subdistribution hazards assumption was satisfied after examining the log(-log) transformation of the crude and weighted nonparametric cumulative incidence function [36] . In all analyses, hydrocodone was chosen as the referent treatment because it is the most commonly prescribed opioid in nursing homes and facilitated comparison to prior studies [2, 12] . In secondary analyses, we estimated HR SD and cumulative risk over progressively longer periods of follow-up to understand how risk may vary as length of opioid use increased (1-30 days, 1-60 days, 1-90 days) [47] .
We conducted stratified analyses by prescribed dosage strength to examine whether the primary associations were modified by initiating dose. Because the specific opioid and dose are simultaneously initiated, we reweighted the data for these analyses as the product of the stabilized treatment IPT weights (described above) and stabilized dose IPT weights [48] . Stabilized dose IPT weights were estimated as the probability of being prescribed the specific dose initiated (< 25 mg, 25-49 mg, or ≥ 50 mg OME/day) given treatment in the numerator and the probability of initiating the specific dose given treatment and previously described confounders in the denominator. We formally tested for additive interaction by estimating the relative excess risk due to interaction (RERI) [49] .
We conducted several sensitivity analyses to examine the robustness of our findings: (1) examining the intention-totreat effect of initiating different opioids on fracture hospitalization risk within 180 days of treatment initiation; (2) restricting the outcome to hip fracture hospitalizations to potentially enhance the sensitivity and specificity of the outcome definition; (3) restricting to states where ≥ 10% of treatment episodes were oxycodone because study medications may be more exchangeable in these regions; (4) excluding residents with physical dependence or wheelchair use to examine fracture risk in physically mobile residents; (5) excluding residents with no previously documented pain on the most recent MDS assessment to mitigate concerns of confounding by pain severity; (6) excluding residents with osteoporosis who may be at increased risk for fractures unrelated to opioid use; and (7) bias analyses to examine the minimum strength an unmeasured confounder would need to have with exposure and outcome on the risk ratio scale to completely explain our primary study results [50, 51] .
Our statistical estimates will have a causal interpretation under the following assumptions: consistency (i.e., our treatment groups are well defined and the observed outcome for the treatment received is equal to their counterfactual outcome for that treatment [52, 53] ); no unmeasured confounding, selection bias, or measurement error; positivity (i.e., there is a nonzero probability of receiving every treatment for every combination of potential confounders [53] ); and correct specification of the weights and outcome model. Although these assumptions are likely violated in practice, we believe this framework provides useful guidance for evaluating our results and the extent to which they can be interpreted causally [54] .
All analyses were conducted in SAS 9.4 (SAS Institute, Inc., Cary, NC, USA) and R version 3.4 (R Foundation for Statistical Computing, Vienna, Austria).
Results
We identified 110,862 long-stay residents (of 1,345,693 long-stay residents who were Medicare beneficiaries) who met inclusion criteria and contributed 134,432 treatment episodes to our analysis. Ten percent of initiation episodes were oxycodone, 51.4% were hydrocodone, and 37.9% were tramadol; see Supplementary Table 5 in the ESM for further detail on the inclusion and exclusion of initiation episodes by treatment group for each study criteria. Table 1 shows selected unadjusted baseline characteristics and overall IPT-weighted characteristics of the cohort; see Supplementary Table 4 in the ESM for a complete summary of baseline characteristics in the unweighted and IPT-weighted cohort at baseline. More than half (55.5%) of initiators were ≥ 85 years old, 47.1% had moderate or severe cognitive impairment, three-quarters required extensive assistance to manage their activities of daily living or were physically dependent, 29.5% had self-or staff-reported pain at their most recent MDS assessment, and 32.1% were prescribed two or more psychotropic medications prior to opioid initiation. Before IPT-weighting, oxycodone initiators were on average younger, more likely to be men, with a lower burden of moderate and severe cognitive impairment, but more physical dependence than tramadol or hydrocodone initiators. IPT-weighting reduced imbalances between groups at baseline by standardizing the distribution of potential measured confounders to that of the entire study cohort. All measured confounders had SMDs ≤ 0.1 after IPT-weighting. See Supplementary Fig. 2 in the ESM for information on the distribution of propensity scores before and after IPT-weighting. See Supplementary Figs. 3 and 4 in the ESM for detail on SMDs of potential confounders pre-and post-weighting. Using IPT-weighting to reduce differences in baseline confounders between treatment groups, the cumulative risk of fracture hospitalizations during 180 days of follow-up was 1.8, 1.6, and 1.1 for oxycodone, hydrocodone, and tramadol initiators, respectively ( Table 3 ). The IPT-weighted HR SD of fracture hospitalizations during 180 days of follow-up was 1.08 for oxycodone initiation versus hydrocodone (95% CI 0.79-1.48); weighted HR SD estimates were similar when restricting follow-up to shorter time periods. Tramadol was associated with a lower subdistribution hazard of fractures relative to hydrocodone during 180 days of follow-up (HR SD 0.67, 95% CI 0.56-0.80); these results were consistent when restricting follow-up to shorter time periods.
Oxycodone initiators were more often prescribed doses ≥ 50 mg OME/day (20.2%; mean dose mg OME/day: 39.2; median dose mg OME/day: 32.1) than hydrocodone (6.2%; mean dose mg OME/day: 25.2; median dose mg OME/day: 21.4) or tramadol initiators (1.2%; mean dose mg OME/day: 18.3; median dose mg OME/day: 18.8). When stratifying by dose, the IPT-weighted HR SD for oxycodone versus hydrocodone (< 25 mg OME/day: HR SD 1.36, 95% CI 0.82-2.28; 25-49 mg OME/day: HR SD 0.89, 95% CI 0.56-1.41) differed qualitatively, but there was limited evidence of effect modification on the additive scale (RERI 0.45, 95% CI −0.31 to 1.21). Dose-stratified HR SD for tramadol versus hydrocodone (< 25 mg OME/day: HR SD 0.66, 95% CI 0.53-0.82; 25-49 mg OME/day: HR SD 0.81) were qualitatively similar with limited evidence of additive effect measure modification (RERI −0.19, 95% CI −0.83 to 0.45). We did not test for effect measure modification in the highest dose strata due to the low number of fracture hospitalizations among oxycodone and tramadol initiators.
Alternative analytic approaches were largely consistent with our primary analyses ( In sensitivity analyses examining the robustness of our primary findings to unmeasured confounding, we found that the HR SD between tramadol and fracture hospitalizations during 180 days of as-treated follow-up versus hydrocodone initiation of 0.67 could be explained away by an unmeasured confounder associated with both specific opioid initiated and fracture hospitalization by a risk ratio of 2.35. See Supplementary Figs. 5 and 6 in the ESM for a range of exposure-confounder and confounder-disease associations needed to explain the results of our primary analysis. Supplementary Figs. 2, 3 and 4 in the ESM for further detail on the overall distribution of propensity scores and standardized mean differences before and after IPT-weighting b 110,862 residents contributed 134,432 treatment initiation episodes (17.0% of residents contributed > 1 treatment episode [range 2-6]). Treatment switching was uncommon: 2.4% and 0.01% of residents initiated 2 or 3 different treatments, respectively c Cognitive impairment was defined using the Cognitive Function Scale (CFS; range 0-3): cognitively intact (0), mild impairment (1), moderate impairment (2), and severe impairment d Physical limitations were defined using the Activities of Daily Living Self-Performance Hierarchy (range: 0-6): no/mild limitations (0-2), extensive limitations (3-4), and physical dependence (5-6) e Resident pain in the 5 days preceding the most recent Minimum Data Set (MDS) assessment before treatment initiation was based on self-report when the resident was able to and staff assessment otherwise f Based on antipsychotics, antidepressants, anxiolytics, and hypnotics g See Supplementary Table 4 in the ESM for further detail on specific classes of antidepressants prescribed (e.g., tricyclics) by study drug initiated h Anxiolytics and hypnotics were measured in the 7 days before the most recent MDS assessment because benzodiazepines were not covered by Part D in 2011-2012 
Discussion
Fracture risk may be important to residents and their caregivers when determining which opioid to initiate given their devastating sequelae, including reduced quality of life [20] , functional decline [20] , and death [20, 21] . In this newuser, IPT-weighted retrospective cohort study of long-stay nursing home residents, we found that initiating tramadol was associated with reduced fracture hospitalization rates during 180 days of as-treated follow-up, whereas oxycodone initiators had similar rates of fracture hospitalizations to hydrocodone initiators. These results are largely consistent with a prior study of the comparative safety of opioids in community-dwelling older adults [12] . Yet, we observed a reduced fracture rate among residents initiating opioids relative to what has been documented in communitydwelling populations [12, 56, 57] . We believe this work provides further context for weighing the risks when initiating Table 3 Fracture hospitalizations by opioid initiated among older nursing home residents during as-treated follow-up (N = 110,862 residents; 134,432 treatment episodes)
CI confidence interval, HR SD subdistribution hazards ratio, IPT inverse probability of treatment, OME oral morphine equivalent a Fracture hospitalizations per 100 person-years b We found no evidence that higher doses (25-49 mg OME/day vs < 25 mg OME/day) increased the subdistribution hazard of fracture risk on the additive scale for hydrocodone and oxycodone (Relative Excess Risk due to Interaction [RERI] = 0.45, 95% CI −0.31 to 1.21) or hydrocodone and tramadol (RERI = − 0.19, 95% CI −0.83 to 0.45). We did not compare those initiating doses ≥ 50 mg OME/day due to the low number of fracture hospitalizations in this group c Suppressed in accordance with Centers for Medicare and Medicaid Service's cell size suppression policy because there were < 11 events commonly used opioids, though we also note the limitations of our study and directions for future research.
Our results are consistent with, albeit less pronounced than Solomon and colleagues' study, which found that community-dwelling elders initiating tramadol had 0.32 times the rate of fractures as matched hydrocodone initiators, and oxycodone initiators had 1.02 times the rate of fractures as hydrocodone initiators [12] . Solomon et al.'s study population had a higher rate of fractures among hydrocodone (26 per 100 person-years), oxycodone (25 per 100 person-years), and tramadol initiators (7 per 100 person-years) than our study population. Although some of this difference may be due to how fractures were operationalized (e.g., hospitalization claims alone [current study] versus outpatient and hospitalization claims), the limited mobility of long-stay nursing home residents may modify and lower the potential risk of fractures following opioid initiation in comparison with community-dwelling older adults [55] , especially if the primary mechanism of action between opioids and fractures among older adults is through acute neurological effects [12, 56, 57] rather than hypogonadism or lowering bone mineral density [58, 59] . This was supported by the heightened rates of fracture hospitalizations that we observed in analyses restricted to residents without total physical dependence or wheelchair use who had fracture hospitalization rates per 100 person-years ranging from 7.3 (tramadol; HR SD versus hydrocodone 0.74, 95% CI 0.57-0.99) to 21.3 (oxycodone; HR SD versus hydrocodone 1.55; 95% CI 0.85-2.85). Mobility may matter when evaluating opioid and fracture risk in nursing homes, with higher physical dependence inversely associated with fractures in some [37, 60, 61] but not all previous studies [62] . Tramadol is commonly prescribed in nursing homes to manage pain [2, 3] and produces analgesia through two mechanisms-weak μ-opioid receptor affinity and serotonin and norepinephrine reuptake inhibition [9] . Because of this unique dual mechanism of action, residents initiating tramadol may on average have lower somnolence, dizziness, and fall risk compared with hydrocodone or oxycodone initiators. However, few head-to-head trials of these commonly used opioids have been conducted to provide further detail on how they may influence fracture risk, particularly among older adults [63, 64] . Although tramadol has a similar safety profile to hydrocodone in terms of somnolence and dizziness in younger populations treated for acute pain [65, 66] , it is unclear if these findings extend to older adults with chronic pain. Further work is needed to elucidate potential mechanisms by which tramadol and other commonly used opioids may cause adverse events among older nursing home residents.
All opioid initiators in our study had a higher rate of fracture hospitalizations (2.8 [tramadol]-3.8 [oxycodone] hip fractures per 100 person-years) than previously reported among long-stay nursing home residents overall (2.3 hip fractures per 100 person-years) [17] . This higher rate among opioid initiators versus non-users is consistent with prior work in community settings and should be kept in mind when initiating any opioid regardless of treatment setting [67] [68] [69] . However, the risks of other adverse events must also be considered. For example, tramadol is associated with rare but potentially life-threatening adverse drug events including serotonin syndrome and hypoglycemia [70, 71] . Finally, nursing home residents are at increased risk of dying compared with community-dwelling adults and may have different goals of care that mitigate concerns of fractures in favor of analgesia or pain relief. Hydrocodone and tramadol initiators died at slower rates (29.1-31.7 deaths per 100 person-years) than the overall long-stay nursing home population (37.5 per 100 person-years) [17] . However, oxycodone initiators were dying at a faster rate (60.9 per 100 person-years); further work is needed to understand whether oxycodone increases mortality risk relative to other opioids as has been documented in community settings [12] .
This study has several unique strengths. We used an active comparator, new-user design to compare three commonly used treatments in nursing homes. This design reduces concerns of confounding by indication and selection bias introduced by comparing incident and prevalent users [72, 73] . Compared with prior studies examining fracture risk in older adults [12, 56, 57, 67] , we had enhanced information from the MDS 3.0 on potential confounders including pain, cognitive impairment, and physical functioning that are not normally available in studies relying on Medicare claims alone. Using IPTweighting, we achieved good balance of measured baseline confounders; such analytic strategies are not always used despite their advantages when the outcome is rare and there are many potential confounders [56, 68, 74] .
This study has several limitations that may limit the causal interpretation of our effect estimates. Although we were able to adjust for confounders not normally available in observational research (e.g., physical functioning), we cannot rule out unmeasured confounding. Further, we did not adjust for potential facility-level and other environmental characteristics that may affect fracture risk. In bias analyses, a measured confounder with a risk ratio of 2.35 with both tramadol and fracture hospitalizations would be needed to attenuate our primary finding. This is above and beyond the strength of measured residentand facility-level confounders with opioids and fractures in this and other studies, but is still possible [3, 37, 75] . We likely undercounted fractures (i.e., reduced sensitivity) by focusing solely on hospitalizations. Our estimates of overall cumulative fracture risk are thus conservative. Our HR SD estimates are expected to be biased towards the null assuming nondifferential misclassification. We assumed that loss to follow-up was nondifferential across treatment groups. We focused only on the most commonly initiated opioids in nursing homes and cannot comment on the comparative safety of initiating other opioids [3, 76] . We measured opioids using claims data and could not distinguish between as-needed (pro re nata) or scheduled use. Such limitations may be addressable in future research using electronic medication administration records to more accurately measure daily opioid use. Our effect measure modification analyses were underpowered. Finally, we assumed that propensity score models and outcome models were correctly specified, though we flexibly parameterized potential confounders (including several categories rather than dichotomizing variables, including higher-order terms for continuous variables) to mitigate these concerns.
In conclusion, we found that initiating tramadol relative to hydrocodone was associated with lower fracture hospitalization risk among older adults living in nursing homes. This may be of particular relevance for persons at heightened risk for falls or who are otherwise concerned about falling. Although this finding is consistent with prior work among community-dwelling older adults, the overall risk of fractures was lower than previously documented in community settings. Further work is needed to elucidate potential mechanisms between opioids and fracture hospitalization risk, as well as whether initiating opioids is associated with other adverse events (e.g., mortality).
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